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The androgen receptor (AR) is a critical effector of prostate cancer development and progression.The
dependence of this tumor type on AR activity is exploited in treatment of disseminated prostate cancers,
wherein ablation of AR function (achieved either through ligand depletion and/or the use of AR antagonists)
is the first line of therapeutic intervention.These strategies are initially effective, and induce a mixed response
of cell cycle arrest or apoptosis in prostate cancer cells. However, recurrent, incurable tumors ultimately arise
as a result of inappropriately restored AR function. Based on these observations, it is imperative to define
the mechanisms by which AR controls cancer cell proliferation. Mechanistic investigation has revealed that
AR acts as a master regulator of G1-S phase progression, able to induce signals that promote G1
cyclin-dependent kinase (CDK) activity, induce phosphorylation/inactivation of the retinoblastoma tumor
suppressor (RB), and thereby govern androgen-dependent proliferation.These functions appear to be
independent of the recently identified TMPRSS2-ETS fusions. Once engaged, several components of the cell
cycle machinery actively modulate AR activity throughout the cell cycle, thus indicating that crosstalk between
the AR and cell cycle pathways likely modulate the mitogenic response to androgen. As will be discussed,
discrete aberrations in this process can alter the proliferative response to androgen, and potentially subvert
hormonal control of tumor progression.
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Prostate cancer is dependent on
androgen action
Prostatic adenocarcinoma is the most frequently
diagnosed malignancy and second leading cause of
cancer death amongst men in the United States [Jemal
et al., 2005]. Localized prostate cancer can be definitively
treated by surgical resection or through radiation therapy
[Catalona et al., 1999; Denmeade and Isaacs, 2002; Dorff
et al., 2006; Swanson, 2006]. However, invasive or even
micrometastatic disease presents a clinical challenge, as
these tumors respond poorly to standard cytotoxic
regimens that act through genomic insult.Therefore,
prostate cancers are treated based on a unique
characteristic, in that they are exquisitely dependent on
androgen for development, growth, and survival [Balk,
2002; Culig and Bartsch, 2006; Jenster, 1999; Klotz,
2000]. Androgen ablation triggers cell death or cell cycle
arrest of prostate cancer cells [Agus et al., 1999;
Denmeade et al., 1996; Huggins and Hodges, 1972;
Isaacs, 1984; Knudsen et al., 1998; Kyprianou and Isaacs,
1988].Thus, androgen ablation remains the primary
course of treatment for all patients with metastatic disease
[Jenster, 1999; Klotz, 2000; Loblaw et al., 2004; Sowery
et al., 2007].These therapies are initially effective, and
result in disease remission. However, recurrent tumors
arise within a median of 2-3 years, wherein androgen
signaling has been inappropriately restored [Feldman
and Feldman, 2001]. At present, few therapeutic regimens
have been described to effectively manage recurrent
prostate cancers, and this is considered an incurable
stage of the disease. Given the dependence of prostate
cancer cells on the androgen signaling axis, a concerted
effort has been undertaken to determine the
mechanism(s) by which androgens induce prostate cancer
cell proliferation and survival.
Androgen receptor regulation in prostate cancer
Androgen exerts its biological effects through the
androgen receptor (AR), a member of the nuclear receptor
superfamily that acts as a ligand dependent transcription
factor [Evans, 1988; Mangelsdorf et al., 1995; Shand and
Gelmann, 2006;Trapman and Brinkmann, 1996].
Testosterone is the most abundant androgen in the sera,
but in prostatic epithelia is converted to a more potent
androgen, dihydrotestosterone (DHT) through the action
of a resident enzyme, 5α-reductase [Russell and Wilson,
1994;Wilson, 1996]. Prior to ligand binding, the AR is
held inactive through association with heat shock proteins
and is precluded from DNA binding. Ligand binding
releases the inhibitory heat shock proteins, and the
receptor rapidly translocates to the nucleus, where it binds
DNA as a homodimer on androgen responsive elements
(AREs) within the regulatory regions of target genes
[Gelmann, 2002; Marivoet et al., 1992;Trapman and
Brinkmann, 1996]. Furthermore, recruitment of
coactivators (which contain or recruit histone acetylases)
and chromatin remodeling complexes facilitate
transcriptional initiation, and AR-dependent gene
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and Chang, 2002; Heinlein and Chang, 2004].The
capacity of AR to subsequently induce a gene expression
program that promotes cell cycle progression is clearly
dependent on cell context. For example, during
development and homeostasis it is clear that the stromal
AR plays a major role in stimulating epithelial cell
proliferation; by contrast, it is hypothesized that a
switching mechanism arises during tumorigenesis to
render the proliferative function of AR cell autonomous
in prostate cancer cells.The specific combinations of
cofactors recruited to AREs likely also provide a
mechanism for tissue specific and ligand specific gene
expression.Through these actions, it is apparent that the
AR promotes prostate cancer survival and proliferation
in prostate cancer cells [Balk, 2002; Feldman and
Feldman, 2001].
While the subsets of AR target genes that underlie each
cellular outcome have yet to be clearly defined, discovery
of at least one major AR-dependent target gene, prostate
specific antigen (PSA) [Riegman et al., 1991], has had a
major impact on disease management. Specifically, serum
PSA is monitored clinically to detect early stage disease,
track tumor burden, monitor the efficacy of therapeutic
intervention, and detect the emergence of recurrent
tumors post-therapy [Nash and Melezinek, 2000; Ryan
et al., 2006].Thus, readouts of AR activity are critical for
the assessment of disease progression and therapeutic
outcome. In addition, it has been recently discovered that
chromosomal translocations occur with significant
frequency in prostate cancer which render the potentially
pro-proliferative ETS genes (ERG, ETV1, or ETV4) under
control of the AR-induced TMPRSS2 promoter/enhancer
[Demichelis et al., 2007;Tomlins et al., 2005;Wang et
al., 2007]. However, subsequent functional investigations
suggest that the TMPRSS2-ETS fusions may principally
exert their effects through alteration of tumor phenotypes
other than cell proliferation. For example, overexpression
of ETV1 in normal or transformed prostatic epithelia had
no impact on cellular proliferation rates or cell cycle
progression, but facilitated invasion of these models
[Tomlins et al., 2007].Thus, the contribution of these
fusions to alterations in cell cycle control has yet to be
well resolved. Lastly, it is possible that non-genomic AR
signaling may influence the proliferative program. It is
known that androgen stimulation in AR-positive cells can
trigger rapid activation of the MAPK pathway, and thereby
potentially induce a mitogenic response. Consistent with
this idea, rapid androgen signaling was recently identified
as a major stimulus for meiotic progression in Xenopus
oocytes, and has also been linked to muscle cell
proliferation [White et al., 2005;Yoshioka et al., 2006].
Thus, while the mechanisms underpinning the capacity
of AR to induce a mitogenic program may be diverse and
dependent on cell context, it is clear that ligand-dependent
activation of AR is a limiting factor for engagement of the
cell cycle machinery in prostate cancer cells.
Given these functions, inhibition of AR activity is the major
therapeutic goal for management of metastatic disease,
as achieved via multiple mechanisms [Balk, 2002;
Feldman and Feldman, 2001; Leewansangtong and
Soontrapa, 1999;Taplin and Balk, 2004]. First line
treatment ablates AR function through ligand depletion,
as achieved through either bilateral orchiectomy or the
use of GnRH agonists. Adjuvant or second line therapies
involve the use of direct AR antagonists (e.g.,
bicalutamide) which utilize at least two mechanisms of
action [Chodak, 2005; Klotz, 2006] . First, these agents
compete for DHT binding. Second, selected AR
antagonists trigger the recruitment of transcriptional
corepressors (e.g., NCoR) to AREs, thereby fostering
active repression of AR target gene expression [Shang
et al., 2002]. At the cellular level, androgen ablation
induces cell death or cell cycle arrest, which underpins
tumor regression [Agus et al., 1999; Denmeade et al.,
1996; Huggins and Hodges, 1972; Isaacs, 1984; Knudsen
et al., 1998; Kyprianou and Isaacs, 1988]. Effective AR
inhibition is also observed by a loss of detectable serum
PSA. However, this remission is transient, and tumor
recurrence is almost invariably observed [Balk, 2002;
Feldman and Feldman, 2001; Leewansangtong and
Soontrapa, 1999]. Recurrence is typically preceded by a
rise in PSA (also called “biochemical recurrence”)
[Feldman and Feldman, 2001; Klotz, 2000;Trapman and
Brinkmann, 1996], and this observation yielded some of
the first evidence that tumor progression is associated
with inappropriately restored AR function, despite
sustained androgen ablation and/or the use of AR
antagonists. AR re-activation in recurrent tumors occurs
through multiple mechanisms, including AR amplification,
AR mutation, ligand-independent AR activation,
hypersensitivity to a low ligand environment, enhanced
local production of androgens, excessive production of
AR coactivators, and/or as a result of signals that disrupt
AR corepressor function [Chmelar et al., 2007; Feldman
and Feldman, 2001; Stanbrough et al., 2006]. Indeed, it
is now well established that such “androgen independent”
prostate cancer remains exquisitely dependent on AR
function [Chen et al., 2004; Cheng et al., 2006;Yuan et
al., 2006]. Since AR appears to be a key determinant of
prostate cancer growth and progression, it is imperative
to dissect the mechanisms by which AR governs cellular
proliferation in prostate cancer cells.
Mitogenic signaling and the cell cycle
machinery: an overview
Transitions into and within the mitotic cell cycle are
dictated by the coordinate activation of cyclin-dependent
kinase (CDK)/cyclin complexes, wherein cyclin binding
induces the catalytic activity of the kinase [Lee and
Sicinski, 2006; Malumbres and Barbacid, 2007; Sherr,
1996; Sherr and Roberts, 2004]. Mitogenic signaling
pathways generally induce cell cycle progression through
ordered activation of CDK-cyclin complexes, whereas
anti-mitogenic signals that result from extracellular events
(e.g., nutrient depletion) or intracellular insults (e.g., DNA
damage) typically serve to attenuate CDK function.
Although the signals that dictate commitment to the cell
cycle are often cell type-specific, the core machinery that
drives the cell cycle engine is well conserved. Prior to
mitogenic stimulation cells can exit the cell cycle and
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several key gatekeepers of cell cycle transitions are
invoked to prevent unscheduled cell cycle progression.
Paramount amongst these is activation of the
retinoblastoma tumor suppressor protein (RB), which
assembles transcriptional repressor complexes on the
promoters of target genes that are required to initiate
DNA replication (e.g., cyclin A, PCNA) [Knudsen and
Knudsen, 2006]. Many such critical RB target genes are
primed for activation by residence of activator E2F/DP1
complexes on the promoter regions, but the transcriptional
repressor complexes recruited by RB (which include
histone deacetylases, SWI/SNF chromatin remodeling
complexes and/or polycomb group proteins) act as potent
inhibitors of transcriptional activation [Johnson and
Degregori, 2006].Thus, mitogenic stimuli must act to
balance RB function, and do so through activation of
CDK-cyclin complexes.
Mitogenic stimuli typically trigger accumulation of D-type
cyclins (cyclins D1, D2, and/or D3), which can bind and
activate the early G1 kinases CDK4 or CDK6 [Lee and
Sicinski, 2006; Sherr and Roberts, 2004]. D-cyclin
production is a tightly regulated process, which has been
most extensively studied with cyclin D1 [Alao, 2007;
Gladden and Diehl, 2005; Knudsen, 2006].The cyclin D1
transcript is controlled at the level of mRNA production,
stability, splicing, and translation. Once produced, cyclin
D1 action is subjected to further regulation at the level of
subcellular localization, targeted degradation, and CDK4/6
binding [Alt et al., 2000; Gladden et al., 2006].These
latter processes appear to involve p21
Cip1, which was
originally classified as a CDK inhibitor.This classification
may be overly simplistic, as while p21
Cip1 can inhibit CDK2
complexes, p21
Cip1 is conversely important for promoting
formation, activation and nuclear enrichment of
CDK4/6-cyclin D complexes [Alt et al., 2002; Cheng et
al., 1999; LaBaer et al., 1997; Sherr and Roberts, 1999].
Once active, the principal cell cycle function of
CDK4/6-cyclin D complexes is to initiate RB
phosphorylation.The concept that this is the major cell
cycle function of CDK4/6 is supported by the observation
that RB-deficient tumor cells are resistant to cell cycle
arrest induced by inhibition of the kinase [Lukas et al.,
1995].Thus, loss of RB in cancer is proposed to bypass
the requirement for this early event in cell cycle
progression.
Although RB phosphorylation/inactivation is initiated by
CDK4/6, this only partially compromises the RB
transcriptional repressor function [Knudsen and Knudsen,
2006]. Subsequent to this event, a downstream kinase
(CDK2) is responsible for completing RB phosphorylation
and thereby extinguishing its repressor function. Critically,
the requisite cyclins associated with CDK2, cyclins E and
A, are themselves regulated via RB-mediated
transcriptional repression.Thus, CDK2-cyclin complexes
constitute a feed-forward mechanism to stimulate cell
cycle progression through modulation of RB. In addition,
cyclin E- and cyclin A-assembled complexes impinge on
additional substrates that promote activation of the DNA
replication machinery, centrosome duplication, and
histone gene expression. Recent findings demonstrate
that these activities are associated with both catalytic
(CDK2 kinase dependent) and non-catalytic functions
[Geng et al., 2007; Lee and Sicinski, 2006]. Subsequently,
transition through the remainder of the cell cycle (G2 and
M phase) is driven by ordered activation of CDK1-cyclin
A and CDK1-cyclin B complexes [Shapiro, 2006]. Cyclin
B production steadily rises in G2; once reaching a
threshold level, mitotic entry ensues dependent on this
kinase. CDK1-cyclin B activity continues to increase
throughout early mitosis until anaphase, wherein rapid
degradation of cyclin B (and thereby loss of CDK1 activity)
triggers mitotic exit and completion of the cell cycle [Pines,
2006; Shapiro, 2006].
To counterbalance this sophisticated coordination of
CDK-cyclin activation, mechanisms exist to halt the cell
cycle in the presence of cellular insult. RB typically
remains hyperphosphorylated/inactivated until mitotic
exit, when the “braking” action of the RB tumor suppressor
is reset by phosphatase activity. However, many
anti-proliferative signals result in RB
dephosphorylation/activation, thus inducing RB-dependent
cessation of cell cycle progression. For example, DNA
damage signals that induce p53-mediated p21
Cip1
induction to high levels can cause downregulation of
CDK2 activity and thereby prevent RB phosphorylation
[Sherr and Roberts, 2004]. Alternatively, the related CDK2
inhibitor p27
Kip1 is often induced by signals such as serum
deprivation, thus acting through similar pathways to halt
cell cycle progression [Nickeleit et al., 2007]. From these
observations, it is apparent that the G1-S cell cycle
machinery plays critical roles in the response to the intra-
and extracellular environments.While these general
principles are conserved in the majority of cell types, it is
increasingly apparent that different mitogenic cues utilize
disparate mechanisms to engage the cell cycle
machinery.
AR governs the cyclin D-RB axis in
prostate cancer cells
Analyses of AR-dependent cell cycle progression in
prostate cancer cells have shown that androgen is a
critical regulator of the G1-S transition (Figure 1). Prostate
cancer cells deprived of androgen arrest in early G1
phase, concomitant with loss of cyclin D1 and cyclin D3
expression, attenuated CDK4 activity (expression
unchanged), and hypophosphorylated/activated
retinoblastoma tumor suppressor [Knudsen et al., 1998;
Xu et al., 2006]. Recent studies revealed that androgen
induces D-type cyclin expression via mTOR-dependent
enhancement of translation [Xu et al., 2006].The ability
of androgen to modulate cyclin D translation is distinct
from mechanisms utilized by other hormones. For
example, estrogen induces cyclin D1 transcription in
breast cancer cells, through the ability of its cognate
receptor (the estrogen receptor, ER) to directly modulate
cyclin D1 regulatory regions [Eeckhoute et al., 2006;
Sabbah et al., 1999].Thus, androgen regulation of early
G1 events is specific to this class of hormone.
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to activate CDK4 and promote phosphorylation of the retinoblastoma (RB) tumor suppressor. In addition, AR-induced expression of p21
Cip1 and
degradation of p27
Kip1 further enhance cycD1/CDK4 and cycE/CDK2-dependent inactivation of RB and allow expression of E2F target genes like cyclin
A (CycA). Cyclin A in turn activates CDK2 to drive G1-S phase transition. Subsequently engaged components of the cell cycle machinery then impinge
on AR to regulate the androgen response. Elevated cyclin D1 acts as in a negative feedback loop to attenuate AR activity, thereby modulating androgen
action. In G2-phase, CDK1 promotes the phosphorylation and activation of AR. However, AR is degraded in M-phase and is purposed to be a “licensing
factor” for DNA replication. Components that suppress AR function are outlined in red, whereas positive effectors of AR activity are outlined in green.
In contrast to the D-type cyclins, cyclin E levels remain
relatively unchanged by androgen withdrawal, indicating
that alteration of cyclin E expression is not a major
mechanism of androgen action [Knudsen et al., 1998; Xu
et al., 2006]. However, cyclin A levels and overall CDK2
activity are diminished upon androgen ablation.These
data are consistent with the observation that androgen
depletion invokes RB activity, as cyclin A is a
well-established target of RB-mediated transcriptional
repression. Furthermore, androgen depletion induces
p27
Kip1, which likely contributes to the observed reductions
in CDK2 activity [Knudsen et al., 1998].This supposition
is consistent with more recent findings which
demonstrated that low p27
Kip1 expression is predictive for
shorter time to disease recurrence in prostate cancer
[Halvorsen et al., 2003]. Similarly, p27
Kip1 loss in the
context of a PTEN mutation promotes a tumorigenic
phenotype in the prostate [Gao et al., 2004]. Interestingly,
upon re-stimulation with androgen, p27
Kip1 is degraded
[Ye et al., 1999]. By contrast, p21
Cip1 expression is lost
upon androgen ablation in prostate cancer cells in vitro,
which correlates with a higher proliferative index in human
tumor specimens [Knudsen et al., 1998; Kolar et al.,
2000].Thus, p21
Cip1 correlates with androgen stimulation
and mitogenic proliferation in prostate cancer.
Remarkably, p21
Cip1 has been validated as a direct AR
target gene [Lu et al., 1999], and its induction upon
androgen stimulation may assist in assembling active
CDK4/cyclin D1 complexes. In agreement with this,
examination of p21
Cip1 in prostate cancer has revealed
that expression is enhanced in tumors, and correlates
with a higher proliferative index and Gleason grade
[Aaltomaa et al., 1999; Baretton et al., 1999].
To date, these observations culminate in a model wherein
androgen induces cyclin D1 accumulation through mTOR,
promotes active CDK4/cyclin D1 assembly (potentially
through p21
Cip1 induction), and facilitates CDK2 activation
through degradation of p27
Kip1.These collective events
result in RB phosphorylation, de-repression of cyclin A
expression, and S-phase progression. Based on this
knowledge of AR function, it could be hypothesized that
aberrations in the cyclin D-RB axis in cancer could
supplant the requirement for androgen and contribute to
disease progression. Investigations challenging this
hypothesis have revealed a significant function for RB in
controlling the response to androgen ablation therapy,
and unique crosstalk mechanisms between the AR and
cell cycle pathways that assist in coordinating and/or
maintaining androgen-dependent cellular proliferation.
RB function in prostate cancer and the
response to AR-directed therapeutics
As discussed above, CDK-mediated RB
phosphorylation/inactivation is a key component of the
proliferative response to AR.These findings suggest that
RB loss may play an influential role in prostate cancer
www.nursa.org  NRS  | 2008 |  Vol. 6 |  DOI: 10.1621/nrs.06001 | Page 4 of 12
Review AR-cell cycle crosstalkdevelopment and/or the response to AR-directed
therapeutics. Consistent with this concept, RB is lost or
inactivated in approximately 30-60% of prostatic
adenocarcinomas through disparate mechanisms [Brooks
et al., 1995; Ittmann and Wieczorek, 1996; Jarrard et al.,
2002;Tricoli et al., 1996]. Accordingly, several model
systems have been developed to more directly probe the
importance of RB function in this tissue.Transgenic
mouse models wherein RB and p53 are inactivated by
SV40 large T- and small T-antigen overexpression in the
luminal epithelia result in high grade PIN and/or prostate
cancer (often with neuroendocrine phenotypes) and can
achieve androgen independence after castration [Gingrich
et al., 1997; Greenberg et al., 1995].Tissue recombination
studies showed that RB-deficient prostatic epithelia give
rise to hyperplastic disease in 40% of grafted samples
when recombined with wild-type rat urogenital
mesenchyme [Wang et al., 2000]. Similarly, conditional
RB deletion in the prostate resulted in focal hyperplasia
that is potentially reminiscent of early stage disease
[Maddison et al., 2004b].These effects are exacerbated
by combinatorial p53 deletion, which results in rapidly
progressing metastatic carcinomas of the prostate [Zhou
et al., 2006].Together, these data are indicative that
inactivation of RB may prime prostate cells to become
cancerous when subjected to other insults.
In addition to these observations, emerging evidence
suggests that RB inactivation may also subvert or weaken
the requirement for AR-mediated cell cycle progression.
Although studies are few in number, one study showed
that RB mRNA expression was low in 36% of patients
that failed combined androgen blockade [Mack et al.,
1998]. Furthermore, by FISH analysis it was reported that
RB loss is almost four times more frequent after hormone
therapy [Kaltz-Wittmer et al., 2000]. Since these data
indicate that RB inactivation and/or deletion may facilitate
the transition to androgen independence, a recent study
challenged this hypothesis in vitro, through
shRNA-mediated depletion of RB in AR-dependent
prostate cancer cells [Sharma et al., 2007]. In these
models, RB depletion did not confer a proliferative
advantage in the presence of androgen; rather
RB-deficient cells failed to elicit a cytostatic response (as
compared to RB-positive isogenic controls) when
challenged with androgen ablation, AR antagonists, or
combined androgen blockade. Not yet considered,
however, is whether loss of RB or deregulation of G1-S
alleviates the need for unliganded AR, and this
determination is the focus of ongoing projects. However,
studies examining the impact RB loss were subsequently
extended to determine the impact of RB loss on the
response to second line chemotherapeutic intervention,
as reports in other cell systems have suggested that loss
of RB-dependent DNA damage checkpoints can sensitize
cells to cytotoxic agents [Harrington et al., 1998; Knudsen
et al., 1998]. Indeed, RB-depleted prostate cancer cells
demonstrated enhanced susceptibility to cell death
induced by a select subset of chemotherapeutic agents.
Combined, these data indicate that RB status may be an
important determinant of the response to AR-directed
therapeutic strategies against prostate cancer, and that
the ability of AR to control the G1-S transition is likely a
critical component for maintaining androgen dependence.
While these studies highlight the importance of AR in
governing the cell cycle machinery, it is becoming
increasingly apparent that substantive crosstalk between
the AR and cell cycle pathways may also contribute to
this process.
Cell cycle regulation of AR
Only a small number of studies have directly examined
the influence of cell cycle on AR activity. Nonetheless,
many of the proteins found to interact with or modulate
AR are also regulated during the cell cycle.These include
proteins whose expression or activity are increased in G0
(RB), G1 to S phase (cyclin D1, cyclin E, Cdk6), or G2
(Cdk1).Therefore, it appears likely that AR activity is
modulated during the cell cycle through interactions with
one or more of these proteins. Moreover, AR may be
further modulated directly during the cell cycle by
transcriptional or post-transcriptional mechanisms, the
latter including alterations in phosphorylation, acetylation,
or ubiquitination that affect transcriptional activity or
stability.The sections below first outline reported
interactions between AR and cell cycle regulated proteins,
and then describe studies that have directly examined
AR during the cell cycle.
Retinoblastoma protein (RB)
Direct interactions between AR and RB have been
reported by two groups based on GST-RB and
mammalian two-hybrid protein interaction approaches
[Lu and Danielsen, 1998;Yeh et al., 1998].The interacting
site on the AR was mapped to the AR N-terminal domain.
Overexpression of RB enhanced AR transcriptional
activity, while AR transcriptional activity was lost in cells
that were RB-negative and was decreased in cells
expressing RB-binding oncogenes. Interestingly, RB has
also been reported to interact with the GR, and RB
overexpression can similarly enhance GR transcriptional
activity [Singh et al., 1995]. However, in contrast to AR,
the GR remains transcriptionally active in RB deficient
cells [Lu and Danielsen, 1998]. Significantly, the GR
coactivation by RB is dependent on Brm, with RB and
Brm forming a complex and both being required for GR
coactivation [Singh et al., 1995]. It is not clear whether a
similar mechanism mediates RB coactivation of AR.
AR has also been found to interact directly with an
RB-associated protein, retinoblastoma-associated Kruppel
protein (RbaK) [Hofman et al., 2003]. RbaK contains a
Kruppel-associated box (KRAB) repressor motif at its
N-terminus, in conjunction with multiple Kruppel type zinc
finger domains, and contributes to the RB-dependent
regulation of E2F transcription factors. RbaK interacts
directly with RB and appears to interact independently
with the AR LBD based on mammalian-two hybrid and
coimmunoprecipitation experiments, with the interaction
being androgen-independent. Although RbaK contains
the KRAB repressor motif, overexpression enhances AR
transcriptional activity by unclear mechanisms. Further
studies are needed to determine precisely how RB and
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biological significance of these interactions for AR activity,
particularly in RB negative PCa [Sharma et al., 2007].
D-cyclins
Although androgen stimulates cyclin D1 accumulation
and concomitant CDK4 activation [Knudsen et al., 1998;
Xu et al., 2006], restoration of cyclin D1 expression under
conditions of androgen ablation is insufficient to drive
androgen-independent proliferation [Fribourg et al., 2000].
Moreover, it was observed that modest elevations of
cyclin D1 in the presence of androgen inhibit (rather than
enhance) cellular proliferation [Burd et al., 2005;
Petre-Draviam et al., 2003].This unexpected capacity of
cyclin D1 to attenuate cell cycle progression is specific
to AR-positive prostate cancer cells, thus suggesting a
putative relationship between cyclin D1 and AR function.
Detailed examination of this interaction revealed an
unexpected and unique role of cyclin D1 in control of AR
activity.
In addition to its ability to modulate CDK4 kinase activity,
increasing evidence has demonstrated that cyclin D1
harbors CDK-independent functions in controlling
transcription factor action [Coqueret, 2002]. Cyclin D1
can directly interact with and modulate a large number
of transcription factors, including v-Myb, DMP1, Sp-1,
and MyoD. A landmark paper demonstrated the relevance
of cyclin D1-mediated transcriptional regulation, wherein
it was shown that the ability of cyclin D1 to interact with
and modulate the CCAAT/enhancer binding protein (and
repress a large subset of genes) has a major
consequence in human tumors [Lamb et al., 2003]. In
addition, it has been recently shown that “kinase
independent” functions of cyclin D1 underlie mammary
gland development, in that in vivo knock-in of cyclin D1
mutants that are unable to activate CDK4 can effectively
reverse the mammary gland phenotype observed in cyclin
D1
-/- mice [Landis et al., 2006].Thus, the
CDK4-independent functions of cyclin D1 appear to serve
critical cellular functions.
The largest class of transcription factors known to be
modulated by cyclin D belong to the nuclear receptor
superfamily, including ER (estrogen receptor α), TR
(thyroid hormone receptor), PPARγ and AR [Coqueret,
2002; Ewen and Lamb, 2004]. In the case of AR, cyclin
D1 binds directly to the N-terminus of the receptor and
blocks conformational changes that are required for
maximal AR activity upon ligand activation (N-C
interaction) [Burd et al., 2005; Petre-Draviam et al., 2005].
Moreover, cyclin D1 associates with histone deacetylase
3 (HDAC3), and recruitment of HDAC activity is essential
for its corepressor functions [Lin et al., 2002;
Petre-Draviam et al., 2005].These actions of cyclin D1
are independent of CDK activity, and a repressor domain
within the protein (encoded by amino acids 142-253) has
been identified which is capable of supporting both cyclin
D1 corepressor functions [Petre-Draviam et al., 2005].
The biological consequence was shown in that even
modest induction of cyclin D1 levels (at stoichiometric
levels with the receptor) are sufficient to suppress both
AR activity and androgen-dependent proliferation in
AR-positive prostate cancer cells [Petre-Draviam et al.,
2003]. As expected, AR-negative prostate cancer cells
are refractory to the repressor function of cyclin D1 [Burd
et al., 2006].These data are consistent with observations
that AR activity is highly regulated as a function of the
cell cycle, wherein cyclin D1 levels inversely correlate
with AR activity [Martinez and Danielsen, 2002].
Moreover, in a mouse model of prostate cancer, cyclin
D1 levels decrease as a function of progression, whereas
cyclin E levels are elevated; this observation led to the
hypothesis of a putative “cyclin switch” that may occur in
prostate cancer progression [Maddison et al., 2004a] ,
although this concept has yet to be validated in human
specimens. Based on these collective observations, it is
hypothesized that cyclin D1 serves as a “negative
feedback switch” to modulate androgen-dependent gene
expression and concomitant cellular proliferation, thereby
governing the strength and duration of the androgen
response. Recent analyses indicated that these
“balancing” functions of cyclin D1 are disrupted in prostate
cancer [Burd et al., 2006; Comstock et al., 2007;
Knudsen, 2006]. In the context of normal prostatic
epithelia, the role of AR is to suppress cell proliferation
and drive differentiation.While not yet examined, it is
possible that cyclin D1 may be important for suppressing
these functions to allow for entry into the cell cycle.
Cdk6
One study found that AR could be coactivated by
transfected Cdk6 [Lim et al., 2005]. Importantly, this
coactivation was not due to sequestration of cyclin D1,
as it was observed in cyclin D1-deficient NIH3T3 cells.
Moreover, coactivation was not prevented by a mutation
in Cdk6 that prevents cyclin D1 binding, or by point
mutations that prevent binding of p16INK4a or inhibit
catalytic activity. Cdk6 was further shown to bind AR
based on coimmunoprecipitation of transfected AR and
Cdk6, and this interaction was similarly not blocked by
the above mutations that prevent cyclin D1 and p16INK4a
binding, or catalytic activity. Stable transfection of Cdk6
into LNCaP cells could enhance androgen stimulated
growth and expression of the androgen regulated PSA
gene. Finally, ChIP experiments indicated that Cdk6 was
part of the AR transcriptional complex that assembles on
the PSA gene. Further studies are clearly needed to
determine the molecular basis for this kinase independent
AR coactivation by Cdk6. Interestingly, Cdk6 expression
in androgen-sensitive prostate cancer cells increases in
response to androgen as cells move from G1 to S phase,
which may then provide a positive feedback loop to further
enhance AR activity [Bai et al., 2005].
Cyclin E
Cotransfection studies carried out with AR, ARE-CAT
reporter, and cyclin D1, E, and A showed that cyclin E
could specifically enhance androgen-stimulated
transcriptional activity [Yamamoto et al., 2000].This
coactivation was not dependent on cyclin E binding to
Cdk2, was independent of cell cycle progression, and
was not observed for GR or PR. Cyclin E transfection into
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endogenous PSA gene. An interaction between AR and
cyclin E was demonstrated by mammalian two-hybrid
protein interaction assays and by coimmunoprecipitation
of transfected proteins.The interaction was mapped to
the AR N-terminal domain, and GST pulldowns indicated
that cyclin E was interacting with a domain at the
C-terminal end of the AR N-terminal domain (amino acids
419-556). As above, further studies are needed to
determine how cyclin E mediates AR coactivation and
whether this interaction may contribute to PCa
development or progression.
CDK-activating kinase (CAK)/Cdk7
CDK-activating kinase (CAK), composed of Cdk7, cyclin
H, and MAT1, mediates the phosphorylations of both
Cdk2 and Cdk1 that are required for full activation and
cell cycle progression. CAK is also a component of the
transcriptional machinery, and can mediate
phosphorylation of ER and RAR [Rochette-Egly et al.,
1997;Trowbridge et al., 1997]. Immunoblotting of anti-AR
immunoprecipitates identified the TFIIH transcription
factor complex, which contains CAK, and further
experiments demonstrated an interaction between AR
and CAK [Lee et al., 2000].Transfection of the individual
CAK proteins could weakly enhance AR transcriptional
activity, with greater coactivation when all three
components were cotransfected. Coprecipitation
experiments in vitro with 
35S-labeled CAK proteins
indicated that Cdk7 and cyclin H could interact with the
AR N-terminal domain.These studies support the
conclusion that TFIIH, as a general transcription factor,
interacts with AR. However, further studies are needed
to determine whether CAK phosphorylates AR or
selectively enhances its activity, or whether it directly
modulates AR during the cell cycle.
Cdc25B
The Cdc25 dual function phosphatases (Cdc25A, B, and
C) mediate the activation of Cdk1 by removal of inhibitory
phosphates from Thr-14 and Tyr-15.The exact functions
of each Cdc25 isoform are not yet clear, but recent data
indicate that Cdc25B specifically dephosphorylates and
activates cyclin B-Cdk1 complexes on centrosomes
[Lindqvist et al., 2005]. Significantly, Cdc25B has also
been identified as a steroid receptor coactivator that can
enhance the activity of ER, PR, GR, and AR [Ma et al.,
2001; Ngan et al., 2003]. Cdc25B can interact directly
with these steroid receptors and stimulate their activity
in a cell-free transcription system. Surprisingly, this
stimulation is not dependent on Cdc25B phosphatase
activity, and its molecular basis remains unclear.
Interestingly, both Cdc25B and Cdc25C were increased
in higher grade prostate cancer, with Cdc25C and a novel
activated splice variant being further increased in PCa
that relapses after androgen deprivation therapy [Ngan
et al., 2003; Ozen and Ittmann, 2005].The interaction
with AR suggests that Cdc25B may contribute to PCa
progression both through effects on AR activation and
cell cycle.
Cdk1
Cdk1 is activated in the G2 phase of the cell cycle and is
the critical Cdk required for mitosis. As noted above, Cdk1
associates with cyclin B and is then activated by removal
of inhibitory phosphates (mediated by Cdc25 isoforms)
and by an activating T loop phosphorylation mediated by
Cdk7.The unliganded AR is phosphorylated primarily at
one serine-proline site in the N-terminal domain (Ser-94),
and is phosphorylated at multiple additional Ser-Pro sites
in response to androgen [Gioeli et al., 2002; Kuiper and
Brinkmann, 1995; Zhou et al., 1995].These are candidate
sites for Cdk1 and other proline-directed kinases, and
studies using Cdk1 transfection and Cdk inhibitors
indicate that Cdk1 phosphorylates at least one site in the
AR N-terminus (Ser-81) [Chen et al., 2006]. Significantly,
transfection of cells with activated Cdk1 was found to
enhance the stability and transcriptional activity of AR.
Conversely, Cdk1 inhibitors decreased AR expression
and transcriptional activity, although these drugs are not
highly specific for Cdk1 and may also effect AR by
targeting other Cdks such as Cdk7 [Chen et al., 2006].
Although Cdk1 phosphorylates AR, site directed
mutagenesis of Ser-81 and of additional Ser-Pro did not
block the ability of Cdk1 to stabilize AR, indicating that
multiple sites may mediate this effect or that Cdk1
stabilizes AR by an indirect mechanism.
Interestingly, an analysis of PCa clinical samples from
patients who had relapsed after androgen deprivation
therapy showed that cyclin B1, cyclin B2, and Cdk1 were
the most highly overexpressed cell cycle regulatory genes
relative to primary untreated tumors [Stanbrough et al.,
2006]. As noted above, both Cdc25B and Cdc25C were
also found to be increased in higher grade prostate cancer
and in tumors that relapsed after androgen deprivation
therapy [Ngan et al., 2003; Ozen and Ittmann, 2005].
Cyclin B expression also increases with disease
progression in the murine TRAMP model of prostate
cancer [Maddison et al., 2004a].Taken together, these
observations suggest that Cdk1 may contribute to AR
activation in advanced cancers. In support of this
hypothesis, the AR activation mediated by low levels of
DHT in C4-2 cells (a subline of LNCaP cells that is
hypersensitive to low androgen levels) could be blocked
by treatment with a Cdk inhibitor [Chen et al., 2006].
Direct assessment of transcriptional AR
activity during the cell cycle
One study has directly examined modulation of AR
transcriptional activity during the cell cycle [Martinez and
Danielsen, 2002]. In this study, AR transcriptional activity
in L929 cells (which express an endogenous AR) was
examined using integrated ARE regulated reporter genes
(MMTV-CAT and probasin-CAT).This study found that
AR transcriptional activity (but not GR activity) was
markedly decreased at the G1/S transition, and was
regained during S-phase. AR protein level was also
reduced at the G1/S transition, but this decrease was not
as marked as the loss of transcriptional activity. A possible
mechanism for the decreased AR expression during G1/S
is increased E2F1, which has been found to suppress
www.nursa.org  NRS  | 2008 |  Vol. 6 |  DOI: 10.1621/nrs.06001 | Page 7 of 12
Review AR-cell cycle crosstalkAR gene expression through binding to the AR promoter
[Davis et al., 2006].
Significantly, an HDAC inhibitor (TSA) could partially
restore AR transcriptional activity at the G1/S transition
without increasing AR protein levels. One interpretation
of this result is that AR recruitment of coactivator proteins
with HAT activity becomes limiting at the G1/S transition,
resulting in decreased histone or AR acetylation.
However, while histone acetylation can enhance
transcription, the role of AR acetylation in regulating AR
activity is not clear [Popov et al., 2007]. Moreover, more
recent data show that HDAC inhibitors decrease AR
expression through inhibition of Hsp90, which must be
deacetylated by HDAC6 for activity [Kovacs et al., 2005].
In any case, the multiple functions of HDACs make it
difficult to clearly assess their roles in regulating AR
activity during cell cycle.
One possible mediator of this loss of AR transcriptional
activity at the G1/S transition is clearly cyclin D1, which
increases during G1 to S progression and can function
as a potent AR corepressor (see above). A second
possible mediator is RB, which can function as an AR
coactivator so that RB hyperphosphorylation at G1/S may
decrease AR activity. Cyclin E may also function as an
AR coactivator, and its increased expression as cells
move into S-phase may contribute to AR reactivation. In
any case, further studies are needed to confirm and
extend the results of this study.
Cell cycle regulation of AR protein
expression
AR protein expression during the cell cycle has been
examined in one study, which used dual-color flow
cytometry to assess AR expression versus binding of
Hoechst dye [Litvinov et al., 2006]. Importantly, binding
of the Hoechst dye is lowest in cells that have just exited
mitosis, and prostate cancer cells (LNCaP, CWR22Rv1,
and LAPC-4) with the lowest Hoechst dye staining had
no detectable AR by flow cytometry. Sorting of this
population with the lowest Hoechst dye binding, followed
by AR immunoblotting, confirmed extremely low AR
protein levels. Immunohistochemistry of cell lines in vitro,
and of in vivo prostate cancers, further showed loss of
AR protein expression in mitotic cells.The authors
suggest that AR in these cells is a licensing factor for
DNA replication, and that this decline in AR protein is
required to license a new round of DNA replication.This
decline is not observed in stromal cells, which are not
androgen-sensitive and express markedly lower levels
of AR, but further studies are needed to establish a link
between AR degradation and DNA synthesis.
This loss of AR protein could be blocked with a
proteosome inhibitor (MG132), indicating that it reflected
proteosomal degradation.These observations suggest
that AR may undergo posttranslational modifications, in
particular ubiquitination, that enhance its degradation
during mitosis. Ubiquitin ligases for AR have been
identified and include E6-AP, CHIP, and MDM2, but their
activities towards AR are not known to be cell
cycle-regulated. Interestingly, Cdk1 has been reported
to stabilize AR protein, although it is not clear whether
this is due to direct AR phosphorylation or other indirect
mechanisms [Chen et al., 2006].Therefore, the decline
in Cdk1 activity that occurs at the end of mitosis may
contribute to the marked increase in AR degradation that
is observed in early G1.
Conclusions
The clinical challenges in prostate cancer center on
controlling the action of the AR, which is required for both
tumor development and disease progression. Selective
pressure brought on by androgen ablation typically results
in a bypass mechanism to activate the receptor in the
absence of ligand, and thereby restore AR-dependent
cellular proliferation.Thus, dissecting the mechanisms
by which AR governs cell cycle progression is
instrumental for the design of new strategies to treat
recurrent disease. It is apparent that activated AR governs
the G1-S progression, and emerging evidence indicates
that cross talk between AR and the downstream cell cycle
machinery serves a critical role in modulating the
androgen response. Aberrations in these processes can
facilitate androgen-independent cellular proliferation, and
may contribute to the development of recurrent tumors.
Future investigations into the consequence of AR-cell
cycle crosstalk in prostate cancer are likely to lead to new
avenues of therapeutic intervention.
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